Naurex to Present Clinical Data for NRX-1074 at 2015 American Society of Clinical Psychopharmacology Annual Meeting

EVANSTON, Ill., June 22, 2015 /PRNewswire/ -- Naurex Inc., a biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the brain and nervous system, will present data from a Phase 2 clinical study of the company's drug candidate, NRX-1074, at the 55^th Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) in Miami.

Ronald M. Burch, M.D., Ph.D., Naurex's chief medical officer, will present these data today at 2:48 p.m. EDT in an oral presentation titled, "A Single Intravenous Dose of the NMDA Receptor Glycine Site Modulator NRX-1074 Dose Dependently Reduced Depression Scores within 24 Hours in Subjects with Major Depressive Disorder (MDD)." This presentation will take place in the Americana Ballroom in Salon 3 of the Loews Miami Beach Hotel.

About Naurex Inc.
Naurex is a clinical stage biopharmaceutical company developing transformative therapies for challenging disorders of the brain and nervous system. The company has built a platform for discovering drugs that enhance synaptic plasticity, or strengthen the network for neural cell communication. Molecules discovered by Naurex achieve this through a novel mechanism that modulates NMDA receptors – rather than shutting them down – resulting in drugs that are both highly effective and well tolerated. Naurex's lead molecule, rapastinel (GLYX-13), has demonstrated rapid, substantial, and sustained reductions in depressive symptoms in multiple Phase 2 clinical studies in major depressive disorder, an area of high unmet need that has seen little innovation in decades. NRX-1074, a next-generation, orally bioavailable drug candidate, has also been well tolerated in clinical studies to date and shown rapid and substantial antidepressant effects in Phase 2. Naurex's platform has yielded a rich pipeline of subtype-selective NMDA receptor modulators with the potential to treat a broad set of psychiatric and neurologic disorders. For more information, visit www.naurex.com

Media Contacts:
Canale Communications
Ian Stone
[email protected]
619-849-5388

Naurex Inc.
Ashish Khanna
Vice President, Corporate Development
[email protected]
847-871-0377

SOURCE Naurex Inc.

Related Links

https://www.naurex.com